List View

By /

Clear

Displaying 2,276 - 2,300 of 2,995

PARP Inhibitors in SCLC

PARP Inhibitors in SCLC

Predictive Biomarkers for SCLC

Predictive Biomarkers for SCLC

Radiation Induced Immune-Response in NSCLC

Radiation Induced Immune-Response in NSCLC

RET and NTRK: The Good, The Bad, The Ugly.... and What’s Coming Up?

RET and NTRK: The Good, The Bad, The Ugly.... and What’s Coming Up?

Role of Interleukins in TIME to Improve Immunotherapy Efficacy

Role of Interleukins in TIME to Improve Immunotherapy Efficacy

Role of Radiotherapy in TIME: Good? Bad? Don’t know?

Role of Radiotherapy in TIME: Good? Bad? Don’t know?

Role of SHP2 Inhibitors Alone or in Combination

Role of SHP2 Inhibitors Alone or in Combination

ROS-1 & B-Raf Inhibitors: New Developments

ROS-1 & B-Raf Inhibitors: New Developments

Stage III Non-Surgical Candidate NSCLC – Controversies in this Arena (Tumors with Actionable Genes and No PD-L1 Expression)

Stage III Non-Surgical Candidate NSCLC – Controversies in this Arena (Tumors with Actionable Genes and No PD-L1 Expression)

Stage III Non-Surgical NSCLC: Optimal Radiation Therapy Approach

Stage III Non-Surgical NSCLC: Optimal Radiation Therapy Approach

Strategies to Target Minimal Residual Disease

Strategies to Target Minimal Residual Disease

Systemic Therapies for Mesothelioma

Systemic Therapies for Mesothelioma

Targeting CEACAM5 and ROR1/ROR2 in NSCLC

Targeting CEACAM5 and ROR1/ROR2 in NSCLC

The Importance of TIME in Cancer Fight: How to Target It?

The Importance of TIME in Cancer Fight: How to Target It?

The New Role of Microbiome in Lung Cancer Immunotherapy

The New Role of Microbiome in Lung Cancer Immunotherapy

The Role of Co-Mutations with Immunotherapy Response in NSCLC

The Role of Co-Mutations with Immunotherapy Response in NSCLC

TROP-2 and AXL as Targets in NSCLC

TROP-2 and AXL as Targets in NSCLC

Updates in Bispecific Antibodies in NSCLC

Updates in Bispecific Antibodies in NSCLC

What Comes After Immunotherapy Failure in Terms of More Immunomodulation (Anti-Angiogenic Agents, IL-15, OX-40 and Others)?

What Comes After Immunotherapy Failure in Terms of More Immunomodulation (Anti-Angiogenic Agents, IL-15, OX-40 and Others)?

What’s After PACIFIC? Can We Raise the Bar?

What’s After PACIFIC? Can We Raise the Bar?

Update on T-Cell Lymphomas

Update on T-Cell Lymphomas

Modern Challenges and New Options for B-cell NHL

Modern Challenges and New Options for B-cell NHL

Most Relevant News in Multiple Myeloma in 2023

Most Relevant News in Multiple Myeloma in 2023

New Developments in CLL

New Developments in CLL

The Era of Antibody Drug Conjugates in NSCLC Targeting Her-2, CEACAM5, TROP-2, and MET

The Era of Antibody Drug Conjugates in NSCLC Targeting Her-2, CEACAM5, TROP-2, and MET